

SAFETY DATA SHEET

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 1 of 14
Print Date 12/08/2018

SAFETY DATA SHEET

RED FDA PILLS

Section 1. Identification

GHS product identifier : RED FDA PILLS
Chemical name : Mixture
CAS number : Mixture
Other means of identification : CC10171159
Product type : solid

Relevant identified uses of the substance or mixture and uses advised against

Product use : Industrial applications. Plastics.

Supplier's details : **POLYONE CORPORATION**
33587 Walker Road, Avon Lake, OH 44012

1 (440) 930-1000 or 1 (866) POLYONE

Emergency telephone number (with hours of operation) : CHEMTREC 1-800-424-9300 (24hrs for spill, leak, fire, exposure or accident).

Section 2. Hazards identification

This mixture has not been evaluated as a whole. Information provided on the health effects of this product is based on individual components. All ingredients are bound and potential for hazardous exposure as shipped is minimal. However, some vapors may be released upon heating and the end-user (fabricator) must take the necessary precautions (mechanical ventilation, respiratory protection, etc.) to protect employees from exposure. After handling, always wash hands thoroughly with soap and water.

OSHA/HCS status : While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture : Not classified.

GHS label elements

Signal word : No signal word.

SAFETY DATA SHEET

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 2 of 14
Print Date 12/08/2018

Hazard statements : No known significant effects or critical hazards.

Precautionary statements

General : Not applicable.
Prevention : Not applicable.
Response : Not applicable.
Storage : Not applicable.
Disposal : Not applicable.
Supplemental label elements : None known.
Hazards not otherwise classified : None known.

Section 3. Composition/information on ingredients

Substance/mixture : Mixture
Chemical name : Mixture
Other means of identification : CC10171159

CAS number/other identifiers

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures
Description of necessary first aid measures

Eye contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated

SAFETY DATA SHEET

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 3 of 14
Print Date 12/08/2018

- Ingestion** : clothing and shoes. Get medical attention if symptoms occur.
: Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Most important symptoms/effects, acute and delayed
Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
Inhalation : No known significant effects or critical hazards.
Skin contact : No known significant effects or critical hazards.
Ingestion : No known significant effects or critical hazards.

Over-exposure signs/symptoms

- Eye contact** : No specific data.
Inhalation : No specific data.
Skin contact : No specific data.
Ingestion : No specific data.

Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Specific treatments : No specific treatment.
Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

Section 5. Firefighting measures
Extinguishing media

- Suitable extinguishing media** : In case of fire, use water spray (fog), foam, dry chemical or CO₂.
Unsuitable extinguishing media : None known.

- Specific hazards arising from the chemical** : No specific fire or explosion hazard.

SAFETY DATA SHEET



RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 4 of 14
Print Date 12/08/2018

- | | | |
|---|---|---|
| Hazardous thermal decomposition products | : | Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides
halogenated compounds |
| Special protective actions for fire-fighters | : | Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. |
| Special protective equipment for fire-fighters | : | Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. |

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

- | | | |
|------------------------------------|---|---|
| For non-emergency personnel | : | No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment. |
| For emergency responders | : | If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". |
| Environmental precautions | : | Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). |

Methods and materials for containment and cleaning up

- | | | |
|--------------------|---|---|
| Small spill | : | Move containers from spill area. Vacuum or sweep up material and place in a designated, labeled waste container. Dispose of via a licensed waste disposal contractor. |
| Large spill | : | Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Vacuum or sweep up material and place in a designated, labeled waste container. Dispose of via a licensed waste disposal contractor. Note: see Section 1 for emergency contact information and Section 13 for waste disposal. |

Section 7. Handling and storage

Precautions for safe handling

SAFETY DATA SHEET


RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 5 of 14
Print Date 12/08/2018

- Protective measures** : Put on appropriate personal protective equipment (see Section 8).
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
- Conditions for safe storage, including any incompatibilities** : Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

None.

- Appropriate engineering controls** : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

- Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
- Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a

SAFETY DATA SHEET

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 6 of 14
Print Date 12/08/2018

higher degree of protection: safety glasses with side-shields.

Skin protection

- Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.
- Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties
Appearance

- Physical state** : solid [Pellets.]
- Color** : RED
- Odor** : Faint odor.
- Odor threshold** : Not available.
- pH** : Not available.
- Melting point** : Not available.
- Boiling point** : Not available.
- Flash point** : Not available.
- Burning time** : Not available.
- Burning rate** : Not available.
- Evaporation rate** : Not available.
- Flammability (solid, gas)** : Not available.
- Lower and upper explosive (flammable) limits** : **Lower:** Not available.
Upper: Not available.
- Vapor pressure** : Not available.
- Vapor density** : Not available.
- Relative density** : Not available.
- Solubility** : Not available.
- Solubility in water** : insoluble in water.
- Partition coefficient: n-octanol/water** : Not available.

SAFETY DATA SHEET


RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 7 of 14
Print Date 12/08/2018

Auto-ignition temperature : Not available.
Decomposition temperature : Not available.
SADT : Not available.
Viscosity : **Dynamic:** Not available.
Kinematic: Not available.

Section 10. Stability and reactivity

Reactivity : No specific test data related to reactivity available for this product or its ingredients.
Chemical stability : Stable under recommended storage and handling conditions (see Section 7).
Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.
Conditions to avoid : Keep away from extreme heat and oxidizing agents.
Incompatible materials : Keep away from strong acids.
Oxidizer.
Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

This mixture has not been evaluated as a whole for health effects. Exposure effects listed are based on existing health data for the individual components which comprise the mixture.

Information on toxicological effects
Acute toxicity

Conclusion/Summary : Mixture. Not fully tested.

Irritation/Corrosion
Conclusion/Summary

Skin : Mixture. Not fully tested.
Eyes : Mixture. Not fully tested.
Respiratory : Mixture. Not fully tested.

Sensitization
Conclusion/Summary

Skin : Mixture. Not fully tested.
Respiratory : Mixture. Not fully tested.

SAFETY DATA SHEET

**RED FDA PILLS**

Version Number 1.2
Revision Date 11/06/2018

Page 8 of 14
Print Date 12/08/2018

Mutagenicity

Conclusion/Summary : Mixture.Not fully tested.

Carcinogenicity

Conclusion/Summary : Mixture.Not fully tested.

Reproductive toxicity

Conclusion/Summary : Mixture.Not fully tested.

Teratogenicity

Conclusion/Summary : Mixture.Not fully tested.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely routes of exposure : Not available.

Potential acute health effects

Eye contact : No known significant effects or critical hazards.
Inhalation : No known significant effects or critical hazards.
Skin contact : No known significant effects or critical hazards.
Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.
Inhalation : No specific data.
Skin contact : No specific data.
Ingestion : No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure**Short term exposure**

SAFETY DATA SHEET

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 9 of 14
Print Date 12/08/2018

Potential immediate effects : Not available.
Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.
Potential delayed effects : Not available.

Potential chronic health effects

Conclusion/Summary : Mixture. Not fully tested.

General : No known significant effects or critical hazards.
Carcinogenicity : No known significant effects or critical hazards.
Mutagenicity : No known significant effects or critical hazards.
Teratogenicity : No known significant effects or critical hazards.
Developmental effects : No known significant effects or critical hazards.
Fertility effects : No known significant effects or critical hazards.

Numerical measures of toxicity**Acute toxicity estimates**

Not available.

Section 12. Ecological information

Toxicity

Product/ingredient name	Result	Species	Exposure
RED FDA PILLS			
Remarks - Acute - Aquatic invertebrates.:	Chemicals are not readily available as they are bound within the polymer matrix.		

Conclusion/Summary : Chemicals are not readily available as they are bound within the polymer matrix.

Persistence and degradability

Conclusion/Summary : Chemicals are not readily available as they are bound within the polymer matrix.

Conclusion/Summary : Chemicals are not readily available as they are bound within the polymer matrix.

SAFETY DATA SHEET



RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 10 of 14
Print Date 12/08/2018

Bioaccumulative potential

Not available.

Mobility in soil

- Soil/water partition coefficient (KOC)** : Not available.
- Other adverse effects** : No known significant effects or critical hazards.

Section 13. Disposal considerations

- Disposal methods** : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

United States - RCRA Acute hazardous waste "P" List: Not listed

United States - RCRA Toxic hazardous waste "U" List: Not listed

Section 14. Transport information

- U.S.DOT 49CFR
Ground/Air/Water : Not regulated for transportation.
- International Air
ICAO/IATA : Not classified as dangerous goods under transport regulations.
- International Water
IMO/IMDG : Not classified as dangerous goods under transport regulations.

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 11 of 14
Print Date 12/08/2018

Section 15. Regulatory information

- U.S. Federal regulations**
- : United States - TSCA 12(b) - Chemical export notification:** None of the components are listed.
 - United States - TSCA 4(a) - Final Test Rules:** Not listed
 - United States - TSCA 4(a) - ITC Priority list:** Not listed
 - United States - TSCA 4(a) - Proposed test rules:** Not listed
 - United States - TSCA 4(f) - Priority risk review:** Not listed
 - United States - TSCA 5(a)2 - Final significant new use rules:** Not listed
 - United States - TSCA 5(a)2 - Proposed significant new use rules:** Not listed
 - United States - TSCA 5(e) - Substances consent order:** Not listed
 - United States - TSCA 6 - Final risk management:** Not listed
 - United States - TSCA 6 - Proposed risk management:** Listed
 - Lead**
 - United States - TSCA 8(a) - Chemical risk rules:** Not listed
 - United States - TSCA 8(a) - Dioxin/Furane precursor:** Not listed
 - United States - TSCA 8(a) - Chemical Data Reporting (CDR):** Not determined
 - United States - TSCA 8(a) - Preliminary assessment report (PAIR):** Not listed
 - United States - TSCA 8(c) - Significant adverse reaction (SAR):** Not listed
 - United States - TSCA 8(d) - Health and safety studies:** Not listed
 - United States - EPA Clean water act (CWA) section 307 - Priority pollutants:** Listed **Antimony**
 - Arsenic**
 - Cadmium**
 - Chromium**
 - Selenium**
 - Lead**
 - Zinc**
 - United States - EPA Clean water act (CWA) section 311 - Hazardous substances:** Not listed
 - United States - EPA Clean air act (CAA) section 112 - Accidental release prevention - Flammable substances:** Not listed
 - United States - EPA Clean air act (CAA) section 112 - Accidental release prevention - Toxic substances:** Not listed
 - United States - Department of commerce - Precursor chemical:** Not listed

SAFETY DATA SHEET

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 12 of 14
Print Date 12/08/2018

Clean Air Act Section 112(b) : Listed
 Hazardous Air Pollutants (HAPs)
 Clean Air Act Section 602 Class I Substances : Not listed
 Clean Air Act Section 602 Class II Substances : Not listed
 DEA List I Chemicals (Precursor Chemicals) : Not listed
 DEA List II Chemicals (Essential Chemicals) : Not listed

US. EPA CERCLA Hazardous Substances (40 CFR 302)

not applicable

SARA 311/312

Classification : Not applicable.

Composition/information on ingredients

No products were found.

SARA 313

	Product name	CAS number	%
Form R - Reporting requirements	Lead	7439-92-1	0 - 0.1
Supplier notification	Lead	7439-92-1	0 - 0.1

SARA 313 notifications must not be detached from the SDS and any copying and redistribution of the SDS shall include copying and redistribution of the notice attached to copies of the SDS subsequently redistributed.

State regulations

Massachusetts : None of the components are listed.
 New York : None of the components are listed.
 New Jersey : None of the components are listed.
 Pennsylvania : None of the components are listed.

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

United States inventory (TSCA 8b) : All components are listed or exempted.

Canada inventory : All components are listed or exempted.

International regulations
Inventory list

SAFETY DATA SHEET

RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 13 of 14
Print Date 12/08/2018

Australia	:	All components are listed or exempted.
Canada	:	All components are listed or exempted.
China	:	All components are listed or exempted.
Europe inventory	:	At least one component is not listed in EINECS but all such components are listed in ELINCS. Please contact your supplier for information on the inventory status of this material.
Japan	:	All components are listed or exempted.
New Zealand	:	All components are listed or exempted.
Philippines	:	All components are listed or exempted.
Republic of Korea	:	All components are listed or exempted.
Taiwan	:	All components are listed or exempted.
Turkey	:	Not determined.
United States	:	All components are listed or exempted.

Section 16. Other information
Hazardous Material Information System (U.S.A.)

Health	/	0
Flammability		0
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

History

Date of printing	:	12/08/2018
Date of issue/Date of revision	:	11/06/2018
Date of previous issue	:	04/24/2018
Version	:	1.2
Key to abbreviations	:	ATE = Acute Toxicity Estimate BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Intermediate Bulk Container IMDG = International Maritime Dangerous Goods LogPow = logarithm of the octanol/water partition coefficient

SAFETY DATA SHEET



RED FDA PILLS

Version Number 1.2
Revision Date 11/06/2018

Page 14 of 14
Print Date 12/08/2018

MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)

UN = United Nations

References

: Not available.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. Particularly this information may not be valid for such material used in conjunction with any other materials or in any process, unless specified in the text.